Danish Breast Cancer Cooperative Group – DBCG: History, organization, and status of scientific achievements at 30-year anniversary

References

• Fischerman K, Mouridsen HT. Danish Breast Cancer Cooperative Group – DBCG. Ugeskr Læger 1977; 139: 2493–4
   PubMedGoogle Scholar
• Engeland A, Haldorsen T, Dickman PW, Hakulinen T, Möller TR, Storm HH, et al. Relative survival of cancer patients. A comparison between Denmark and the other Nordic countries. Acta Oncol 1998; 37: 49–59
   PubMed Web of Science ®Google Scholar
• Andreasen AH, Mouridsen HT, Andersen KW, Lynge E, Mouridsen M, Olesen KP. Prognoseforbedring for brystkræft. Ugeskr Læger 1994; 156: 6512–7
   PubMedGoogle Scholar
• Fisher B, Carbone P, Economu SG, Frelick R, Glass A, Lemer H, et al. L-phenylalanine mustard (L-PAM) in the management of primary breast cancer. N Engl J Med 1975; 292: 117–22
   PubMed Web of Science ®Google Scholar
• Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Brambilla C, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976; 294: 405–10
   PubMed Web of Science ®Google Scholar
• Danish Breast Cancer Cooperative Group. www.dbcg.dk.
   Google Scholar
• Møller, S, Jensen, M-B, Ejlertsen, B, Bjerre, KD, Larsen, M, Hansen Hanne, B, et al. The clinical database and the treatment guidelines programmes of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise. Acta Oncol 2008;47:506–24.
   PubMed Web of Science ®Google Scholar
• EBCTCG, Early Breast Cancer Trialists’ Collaborative Group.Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and on 15-year survival: An overview of the randomised trials. Lancet 2005;366:2087–106.
   PubMed Web of Science ®Google Scholar
• EBCTCG, Early Breast Cancer Trialists’ Collaborative Group.Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomized trials. Lancet 2005;365:1687–717.
   PubMed Web of Science ®Google Scholar
• Hermansen C, Poulsen SH, Jensen J, Langfeldt B, Steenskov V, Frederiksen P, et al. Diagnostic reliability of combined physical examination, mammography, and fine needle puncture (“Triple test”) in breast tumours. Cancer 1987; 60: 1866–71
   PubMed Web of Science ®Google Scholar
• Sundhedsstyrelsens udvalg vedr.“Brystkræft: Tidlig opsporing og undersøgelse”. Sundhedsstyrelsen. 1994.
   Google Scholar
• Sundhedsstyrelsens notat vedr.”Vejledning om diagnostisk udredning af patienter med symptomer på eller hvor der er rejst mistanke om brystkræft”. ( 2. rev. udg.). Sundhedsstyrelsen, 25 oktober, 1999.
   Google Scholar
• Perry NM of behalf of the EUSOMA Working Party.Quality assurance in the diagnosis of breast disease. Eur J Cancer 2001;37:159–72.
   PubMed Web of Science ®Google Scholar
• Cady B. Total mastectomy and partial axillary dissection. Surg Clin North Am 1973; 53: 313–8
   PubMed Web of Science ®Google Scholar
• Blichert-Toft M, Rose C, Andersen JA, Overgaard M, Axelsson C, Andersen KW, et al. Danish randomized trial comparing breast conservation with mastectomy: Six years of life-table analysis. J Natl Cancer Inst Monogr 1992; 11: 19–25
   PubMedGoogle Scholar
• Christiansen, P, Friis, E, Balslev, E, Jensen, D, Møller, S. Sentinel node biopsy in breast cancer: Five years experience from Denmark. Acta Oncol 2008;47:561–68.
   PubMed Web of Science ®Google Scholar
• Blamey, R, Cataliotti L on behalf of the EUSOMA revision committee.The requirements of a specialist breast unit. Chapter 9. In: NM Perry, M Broeders, D de Wolf, et al. European Guidelines for quality assurance in breast cancer screening and diagnosis. 4th ed. Brussels; European Commission: 2006. p 343–354.
   Google Scholar
• Blichert-Toft M, Kroman N. The specialist breast unit and breast surgery as a specialty. Scand J Surgery 2002; 91: 227–31
   PubMedGoogle Scholar
• Cataliotti L, Wolf de C, Holland R, Marrotti L, Perry N, Redmond K, et al. EUSOMA guidelines on the standards for the training of specialised health professionals dealing with breast cancer. Eur J Cancer 2007; 43: 660–75
   PubMed Web of Science ®Google Scholar
• Overgaard, M, Hansen, PS, Overgaard, J, Rose, C, Andersson, M, Bach, F, for the Danish Breast Cancer Cooperative Group 82b Trial, et al.Postoperative radiotherapy in high-risk pre-menopausal women with breast cancer who receive adjuvant chemotherapy. N Engl J Med 1997;337:945–55.
   Web of Science ®Google Scholar
• Overgaard M, Jensen M-B, Overgaard J, Hansen PS, Rose C, Andersson M, et al. Postoperative radiotherapy in high-risk postmenopausal breast cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 1999; 353: 1641–8
   PubMed Web of Science ®Google Scholar
• Knoop AS, Knudsen H, Balslev E, Rasmussen BB, Overgaard J, Nielsen KV, et al. Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to Cyclophosphamide, Methotrexate, and Fluorouracil or Cyclophosphamide, Epirubicin, and Fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 2005; 23: 7483–90
   PubMed Web of Science ®Google Scholar
• Grabau DAa, Jensen M-B, Blichert-Toft M, Andersen JA, Dyreborg U, Carstensen B, et al. The importance of surgery and accurate axillary staging for survival in breast cancer. Eur J Surg Oncol 1998; 24: 499–507
   PubMed Web of Science ®Google Scholar
• Mouridsen, HT, Bjerre, KD, Christiansen, P, Jensen, M-B, Møller, S. Improvement of prognosis in breast cancer in Denmark 1977–2006, based on the nationwide reporting to the DBCG registry. Acta Oncol 2008;47:525–36.
   PubMed Web of Science ®Google Scholar
• Andersen D. Læge og klinisk forsker (editorial). Ugeskr Læger 1991; 153: 2269
   PubMedGoogle Scholar